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Summary
Follicular Lymphoma (FL) is the second most common non-Hodgkin lym-
phoma (NHL) subtype and its course is heterogeneous. At diagnosis, some
patients with FL manifest a detectable leukaemic phase (FL-LP), but this
feature has been seldom described and is poorly characterized. Among 499
patients diagnosed with FL in Lyon-Sud hospital, 37 (74%) had character-
istic FL-LP (by cytological blood smears and flow cytometric analysis). In
addition, 91/1135 FL patients from the PRIMA study presented FL-LP at
study entry. In order to evaluate the outcome of this Lyon-Sud cohort,
FL-LP patients were matched with 111 newly diagnosed FL without LP
according to the Follicular Lymphoma International Prognostic Index
(FLIPI) score, age and treatment. Presence of FL-LP was associated with
shorter progression-free survival (PFS) and overall survival (OS) (P = 0004
and P = 0031, respectively). Presence of FL-LP and high FLIPI score
remained independent prognostic factors in a Cox model for time to pro-
gression (TTP). A number of circulating lymphoma cells (CLC) >4 9 109/l
was the most significant predictor for a shorter TTP in this Cox model. The
prognostic impact of FL-LP on TTP was validated in the PRIMA cohort
(P = 00004). In conclusion, FL-LP is a rare event associated with shorter PFS
and patients with CLC >4 9 109/l have a poorer outcome. These patients
should be monitored carefully to consider alternative therapeutic options.
Keywords: follicular lymphoma, peripheral blood involvement, prognostic
factor, rituximab maintenance.
Follicular Lymphoma (FL) is the second most common non-
Hodgkin lymphoma (NHL) subtype and the most frequent of
the indolent NHL. It is an heterogeneous entity with some
patients presenting an indolent clinical course for one or two
decades, and others developing a much more aggressive dis-
ease and having a shorter survival (Campo et al, 2008). FL
cells proliferate in the germinal centre and are characterized
by the t(14;18) or one of its variants, present in almost 85%
of cases, resulting in overexpression of the BCL2 oncogene.
The Follicular Lymphoma International Prognostic Index
(FLIPI) and the FLIPI2 (Solal-Celigny et al, 2004; Federico
et al, 2009) are used in clinical practice but fail to identify
patients with a truly poor prognosis. While the FLIPI index is
an accurate tool in the rituximab era (Relander et al, 2010),
several prognostic factors are not considered, such as tumour
bulk, serum level of b2-microglobulin or blood involvement.
Indeed FL often involves spleen and bone marrow (BM) but,
in contrast to other indolent NHL at diagnosis, very few
patients present with an overt detectable leukaemic phase
(FL-LP). While a few reports described this finding (Melo
et al, 1988; Chubachi et al, 1993; Hsieh et al, 2006;
Rymkiewicz et al, 2006; Ganguly, 2009; Al-nawakil et al,
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2011), the prognostic impact of this phenomenon has not
previously been evaluated. The aim of this study was to
describe the clinical features of this population and its out-
come. Analysis was performed in a retrospective patient
cohort from the Lyon Sud Hematology Department (Hospices
Civils de Lyon) and then validated in patients accrued in the
PRIMA (Salles et al, 2011) study, a randomized open label
study conducted by the Groupe d’ Etude des Lymphomes de l’
Adulte (GELA) between December 2004 and April 2007.
Patients and methods
Selection of patients
Among 499 patients diagnosed with FL according to the
World Health Organization (WHO) criteria (Campo et al,
2008) (transformation to diffuse large B-cell lymphoma
[DLBCL] and grade 3b FL excluded) in Lyon-Sud Hospital
between January 1992 and January 2012, 37 cases (74%) had
characteristic FL-LP detected by cytological blood smear
analysis and confirmed by flow cytometry at time of diagno-
sis (identified on the basis of j/k monoclonality). All FL
patients had an initial clinical examination and blood tests,
including specific blood smears to look for circulating lym-
phoma cells (CLC), BM biopsy or aspirate, and computer-
ized tomography (CT) body scan for staging. All data
recorded in patients’ files were collected retrospectively and
anonymously coded. For all patients, complete response
(CR) was assessed using standard response criteria (Cheson
et al, 1999), including BM biopsy and CT scan. Immuno-
staining on blood smears or flow cytometry were also rou-
tinely performed on peripheral blood to verify the clearance
of CLC. The study was conducted according to the Hospices
Civils de Lyon ethic institutional guidelines and in accor-
dance with the declaration of Helsinki.
Pathological and biological analyses
Blood smears were centrally reviewed for the study. For flow
cytometric analysis, whole peripheral blood (n = 37) was
stained using 2, 3 or 6 combinations of directly conjugated
monoclonal antibodies (details are provided in Data S1). The
samples were analysed on a Coulter EPICS XL flow cytome-
ter. Additionally, in a subset of patients (n = 15), the expres-
sion of adhesion molecules (CD62L, CD11a, CD18, CD44
and CD54) was analysed on lymph node (LN) samples and
compared to that observed in LN samples of FL without LP
(n = 24). The immunophenotyping and flow cytometric
methods have been previously reported (Traverse-Glehen
et al, 2008). Histopathology samples were centrally reviewed
for the study and classified according to the WHO 2008 clas-
sification (Campo et al, 2008). Immunohistochemical stains
on whole tissue sections were performed to confirm the diag-
nosis of FL and to evaluate the microenvironment. CD68
staining was classified as high or low according to CD68 cell
count (≥or <15/high-power field). In BM biopsy, the percentage
of lymphoma cell infiltration was estimated by counting.
Cytogenetic analysis was performed in 23/37 cases and, in
four patients, the BCL2 rearrangement was studied by fluores-
cence in situ hybridization (FISH) using the appropriate probes
(either IGH/BCL2 or dual color break-apart BCL2 probes –
Vysis, Downer’s Grove, IL, USA). Chromosome studies were
performed as previously reported (Callet-Bauchu et al, 1999).
Identification of patients with FL-LP in the PRIMA
study database
In order to expand and potentially validate findings in a pro-
spective cohort of patients with FL, we used data collected in
the PRIMA study (Salles et al, 2011). The presence of CLC
was a criterion collected prospectively and monitored in the
case report form, but the specific modalities used for the
documentation of this manifestation at study sites were not
available. Hence, it was not possible to provide the distribu-
tion of circulating lymphoma number or to validate the
4 9 109/l threshold in this cohort.
Statistical analysis
Statistical analyses were performed using STATISTICA software
version 7.1 or SASv9.02 (for PRIMA patients). Time to pro-
gression (TTP) was calculated from the time of first treat-
ment initiation (watchful waiting was considered as a first
treatment if decided after initial consideration of manage-
ment options) to time of disease progression. In the PRIMA
study, progression-free survival (PFS) was calculated from
time of registration (time of first therapy initiation) to time
of disease progression. Overall survival (OS) was calculated
from the time of first treatment initiation to time of death
from any cause. Response and progression were defined
using the international response criteria (Cheson et al, 1999,
2007). Survival functions were estimated by the Kaplan-Me-
ier method and compared by log-rank test. Cox regression
analysis was performed to adjust for the effect of prognostic
factors relevant in univariate analysis. Patients’ characteristics
were compared using the Chi-square test. In the cohort of 37
patients with a FL-LP, univariate analysis for TTP including
the different biological and clinical initial characteristics was
performed. To further evaluate the impact of the number of
CLC, a threshold of 4 9 109/l, corresponding to the upper
limit of the normal lymphocyte count, was chosen. P-value
<005 was used to define statistical significance.
Results
Clinical and biological characteristics of Lyon-Sud
patients
Initial characteristics of the 37 patients with FL-LP at diag-
nosis are described in Table I A, B and Table SI. The median
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age was 58 years. All the patients presented with nodal
involvement. Most of the patients had an intermediate
(n = 16) or high (n = 17) FLIPI score and the large majority
of them (n = 26) had a high tumour burden, according to
GELA criteria, at diagnosis (Solal-Celigny et al, 1993). Nine
patients had anaemia and 5 had thrombocytopenia (platelet
count <100 9 109/l).
All the patients had a biopsy specimen except one patient
diagnosed on blood smears, BM aspirate and ascitic fluid
samples, confirmed by flow cytometry and the presence of t
(14;18) on karyotyping. Among the 36 histological samples
available, 33 were LN biopsies and three extra-nodal biopsies
(one of BM, one bone and one liver) with therefore limited
immunohistochemical data. The characteristics are shown in
Table II. All the tumours were CD20, CD10 and BCL2 posi-
tive except two cases that were BCL2 negative but demon-
strated a positive IGH-BCL2 translocation by FISH. All
biopsy samples showed a pattern of inter-follicular dissemina-
tion with CD20, CD10 and BCL2 positive cells outside of the
follicles. Most of them (84%) had a low- or intermediate-
MIB1 score (<10% or 10–50% respectively). There were a
majority (89%) of grade 1–2 FL with low fibrosis score
(85%). Four patients presented a marginal zone differentia-
tion pattern but with the t(14;18) as a hallmark of FL in 3 of
them. Regarding the T-cell microenvironment, CD4+ T cells
were always more abundant than CD8+ T cells. A marked
peri-follicular localization of the CD3+ T cells was observed
in eight cases. The presence of macrophages was assessed by
CD68 expression and classified as high (six cases) or low (26
cases). The follicular dendritic cells meshwork was dense in
17 cases and weak in 16 cases. The median estimate of BM
infiltration for patients with FL-LP was 51% (range 10–90%).
Flow cytometry identified a monotypic CD10 positive B
cell population (n = 29), expressing surface immunoglobulin
M (15/37), G (9/37), A (1/37), M+D (3/37) and M+G (3/37)
(heavy chain was absent in four cases and not determined in
two cases) with monotypic kappa (20 cases) or lambda
(16 cases) light chain restriction (lack of light chain expres-
sion in one case). The median count of CLC was 195 9
109/l (range, 060–12900 9 109/l). Fourteen and six patients
had CLC counts higher than 4 9 109/l and 10 9 109/l,
respectively.
Cytogenetic data at diagnosis were available for 23 patients
(21 by conventional cytogenetics and four by FISH). All but
one expressed the t(14;18), or its t(18;22) variant, and
IGH-BCL2 fusion was found in the four FISH analyses. Many
patients had a complex karyotype (16/21), four presented
with del(6q), two del(17p), three del(10q), three dupBCL2,
one had a tetraploid karyotype, three patients had anomalies
on 9p (p16 and p21 loci), and three on 17q.
Treatment and outcome
All but two patients, who were managed with watchful
waiting, were treated at diagnosis. Thirty-five patients were
treated with chemotherapy at diagnosis, which included
rituximab for 27 patients (most patients received rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone
Table I. Clinical (A) and biological characteristics (B) at diagnosis,
of the 37 patients with FL-LP.
Clinical characteristic N = 37
Age, years, median (range) 583 (28–80)
>60 years 13
≤60 years 24
Sex (Male/Female) 13/24
FLIPI score
Low 4
Intermediate 16
High 17
Splenomegaly
No 14
Yes 23
ECOG-PS
0–1 34
2 or + 3
B symptoms
No 29
Yes 8
High Tumour Burden
No 11
Yes 26
Nodal Involvement
No 0
Yes 37
>4 nodal localizations
No 12
Yes 25
Biological characteristic N = 37
Anaemia (Hb <120 g/l)
No 28
Yes 9
Thrombocytopenia (platelets <100 9 109/l)
No 32
Yes 5
Lymphocyte count
Median (9109/l) (range) 4 (1–130)
% of clonal cells (median, range) 60% (6–99%)
b2-microglobulin >3 g/l
No 15
Yes 22
Lactate dehydrogenase > normal
No 26
Yes 11
CLC: (9109/l) median (range), mean 195 (060–12870), 1279
≤4 9 109/l 22
4–10 9 109/l 9
>10 9 109/l 6
FLIPI, follicular lymphoma international prognostic index; ECOG-
PS, eastern cooperative oncology group performance score; CLC, cir-
culating lymphoma cells.
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(CHOP or CHOP-like regimen). The eight patients treated
before 2003 (when rituximab became routinely available as a
first-line therapy) received CHOP or CHVP regimen (includ-
ing cyclophosphamide, etoposide, adriblastine and predni-
sone). The overall response rate (ORR) was 83% (29/35
patients) and the CR rate was 66% (18 patients reaching CR
and five unconfirmed CR [CRu]), five patients had stable
disease and one progressed during treatment. The median
TTP was 289 months. Actuarial TTP and OS rates were
37% and 86% at 5 years and 31% and 68% at 10 years,
respectively (Fig 1). Among 23 patients achieving a CR or a
CRu, 11 relapsed (between 9 and 74 months from attain-
ment of remission, median 18 months). Five of the six
patients with a partial response (PR) relapsed (at 3, 4, 12, 13
and 31 months from attainment of remission).
Of the 22 patients with refractory disease (n = 6) or fur-
ther lymphoma progression (n = 16), 12 received salvage
therapy followed by autologous stem cell transplantation
(ASCT). Their median TTP from diagnosis was 83 months
while median TTP after ASCT has not yet been reached, with
a 10-year TTP estimate of 68%. Considering all patients, at a
median follow-up of 72 months, eight patients had died, six
from a lymphoma-related cause, including four after histo-
logical transformation.
Regarding the two patients managed with watchful wait-
ing, one died after 24 months of follow-up due to develop-
ment of DLBCL transformation. The other patient is alive
without treatment initiation with a follow-up of 67 years.
Prognostic factors in the 37 patients with FL-LP
To evaluate the impact of CLC count, the threshold of
4 9 109CLC/l, corresponding to the upper limit of the normal
lymphocyte count, was chosen. In univariate analysis (Table
SII), several characteristics were associated with a shorter TTP
in this cohort, namely splenomegaly (P = 0035), presence of
high tumour burden (P = 0017), CLC count (>4 9 109/l,
P = 0026) and b2-microglobulin level (>3 mg/l, P = 0036).
Exploratory multivariate analysis including all these variables
identified splenomegaly (Hazard ratio [HR] = 317; P =
0029) and a CLC count >4 9 109/l (HR = 33; P = 0009) as
independent prognostic factors for TTP.
Patients presenting a high CD68 expression tended to have
a shorter median TTP (7 months) than the others
(43 months); this difference was not statistically (P = 02)
significant due to the low number of patients analysed.
Matched pair analysis for clinical and prognostic factors
To further evaluate the impact of FL-LP on TTP and OS, we
performed a 1:3 matched pair analysis without replacement
according to FLIPI score, age, treatment type (observation
versus chemotherapy, with or without rituximab) and
treatment period (before or after 2000) (Bland & Altman, 1994;
Sorensen & Gillman, 1995). All 37 patients were successfully
matched with 111 newly diagnosed patients presenting with FL
without LP (Table SIII). In the 111 matched patients with FL,
Table II. Prognostic analysis in the matched population.
Univariate Analysis N = 148
Median TTP
(months)
Median OS
(months)
Cox Model 1: P-value
and HR for TTP
(N = 120)
Cox Model 2: P-value
and HR for TTP
(N = 120)
Cox Model: P-value
and HR for OS
(N = 120)
CLC P = 00035 P = 0031 P = 00085
No versus (N = 111) 89 NR HR = 22
Yes (N = 37) 29 NR 95% CI (145–477)
CLC P = 000012 P = 00019 P = 00006 P = 0046
≤4 9 109/l (N = 133) vs 89 NR HR = 357 HR = 37
>4 9 109/l (N = 15) 15 NR 95% CI (174–724) 95% CI (102–129)
FLIPI P = 00013 P = 00014 P = 00034 P = 0037 P = 0049
Low and intermediate (N = 81) NR NR HR = 2 HR = 137 HR = 195
High (N = 67) 432 133 95% CI (146–369) 95% CI (101–24) 95% CI (1–379)
Β2-microglobulin P = 0017 P = 0085 P = 015 P = 0066 P = 029
<3 mg/l (N = 79) 88 NR HR = 152 HR = 192 HR = 188
>3 mg/l (N = 41) 45 NR 95% CI (085–271) 95% CI (092–283) 95% CI (057–61)
HR, Hazard Ratio.
Univariate prognostic analysis for time to progression (TTP) and overall survival (OS) in the matched population. N = 148 patients, 37 with cir-
culating lymphoma cells (CLC) and 111 without. In this population the presence of CLC, a high Follicular Lymphoma International Prognostic
Index (FLIPI) score and a high b2-microglobulin level were associated with a shorter TTP. Survival was significantly shorter for patients with high
FLIPI score or CLC at diagnosis, but was not impacted by high b2-microglobulin level.
In a Cox regression model for TTP, high FLIPI score, and presence of follicular lymphoma with a detectable leukaemic phase (FL-LP) remained
independently associated with a shorter TTP. In a Cox regression model for OS, FLIPI score was the only significant predictive factor (data not
shown). In a second Cox regression model for TTP, including CLC count (higher than 4 9 109/l versus absent or lower than 4 9 109/l) instead
of CLC presence or absence as variable, CLC count >4 9 109/l and FLIPI were two independent prognostic factors associated with a shorter TTP
and OS.
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median TTP was 89 months with 5- and 10-year TTP estimates
of 64% and 41%, respectively. Five- and 10-year survival
estimates were 97% and 91%, respectively.
Prognostic analysis for TTP in the whole population of
37 patients with FL-LP and the matched 111 patients
without FL-LP, including b2-microglobulin level, FLIPI score
and presence of FL-LP showed that high FLIPI score
(P = 00013), presence of FL-LP (P = 00035) and high
b2-microglobulin level (P = 0017) were all significantly asso-
ciated with an inferior outcome. In a Cox regression model
for TTP including these three variables (performed in 120/
148 patients with complete data), only high FLIPI score
(P = 00034; HR = 2) and the presence of FL-LP
(P = 00085; HR = 22) remained independently associated
with shorter TTP (Table II). In a Cox regression model for
OS, FLIPI score was the only significant predictive factor
(data not shown). Similar results were found when patients
under watchull waiting were excluded from the analysis (two
in the FL-LP cohort and six in the matching cohort) (data
not shown).
Comparison of pathological characteristics in the FL-LP
and the matched population
Of the 111 patients without LP, 108 had a BM biopsy at
diagnosis and 53 of those showed lymphomatous infiltration
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Fig 1. Time to progression and overall survival
in the population of patients with FL-LP (A)
Progression-free survival in the 37 patients pre-
senting with follicular lymphoma with a detect-
able leukaemic phase (FL-LP) at diagnosis.
Median time to progression (TTP) is
29 months. TTP estimates were 37% at 5 years
and 31% at 10 years. (B) Overall survival in
the 37 patients presenting with FL-LP at diag-
nosis. Overall survival estimates were 86% at
5 years and 68% at 10 years.
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with a median infiltration rate of 15% (range from <5% to
70%). The median estimate of BM infiltration for patients
with FL-LP was 51% (range 10–90%), which is significantly
higher than the estimated infiltration of the 53 patients with-
out LP (P < 00001, Mann–Whitney U-test).
Additional flow cytometric analysis was performed on
lymph nodes cells to evaluate the expression of adhesion
molecules and results are detailed in Table SIV.
Validation on patients from the PRIMA study
To validate these findings in a prospective cohort of patients
with FL, data collected from the PRIMA study were analysed
(Salles et al, 2011). In the PRIMA trial, patients with previ-
ously untreated FL requiring systemic therapy were random-
ized after eight cycles of induction therapy (consisting of
R-CHOP or R-CVP or R-FCM [rituximab, fludarabine,
cyclophosphamide, and mitoxantrone] according to investi-
gator preferences) between maintenance with rituximab for
2 years or observation. Among the population of 1135
patients with histologically-confirmed FL, 92 presented
FL-LP (9%). After induction therapy they had the same ORR
as patients without LP (ORR of 935% and 905% for
patients with and without FL-LP, respectively, P = 0455).
However, statistical analysis for PFS showed that FL-LP
patients had a shorter PFS than those without LP when
assessed from registration (P = 00004, with a median PFS of
398 months versus 651 months) (Fig 2). No significant
difference in terms of OS according to FL-LP was observed.
A heterogeneous population
To further analyse the impact of CLC on outcome, patients
were categorized according to the number of CLC. The
threshold of 4 9 109CLC/l, corresponding to the upper limit
of the normal lymphocyte count, was chosen. Given the
expected heterogeneity of CLC assessment in different
PRIMA centres, this analysis was only performed on the
Lyon-Sud retrospective cohort. As mentioned above, in the
population of 37 patients with FL-LP, those with >4 9 109/l
CLC had a poorer outcome than those with ≤4 9 109/l.
Interestingly, in the matched study, FL-LP patients with
≤4 9 109/l CLC had a similar TTP to those without (Figure
S1) (P = 04, median 66 and 89 months respectively). Fur-
thermore, patients without FL-LP or with ≤4 9 109/l CLC
had actuarial 5- and 10-year OS rates of 96% (standard error
[SE] 17%) and 88% (SE 48%) vs. 73% (SE 13%) and 52%
(SE 158%) for patients with >4 9 109/l CLC, respectively
(P = 00019) (Fig 3). When CLC >4 9 109/l (instead of CLC
>0) was used as a cut-off point in the Cox regression model
for TTP together with b2-microglobulin and FLIPI score, the
most significant predictor for a shorter TTP was CLC
>4 9 109/l (P = 0006; HR = 357) as compared to FLIPI
score (P = 0037; HR = 137) and b2-microglobulin
(P = 0066; HR = 192). In a Cox regression model for OS,
CLC >4 9 109/l (P = 0046; HR = 37) and FLIPI score
(P = 0049; HR = 195) were also significant predictors
(Table II).
Discussion
Although few reports include a substantial number of
patients with FL-LP, this clinical characteristic was found
in 74% and 9% of FL patients in a reference hospital
department and in a prospective clinical trial recruiting only
those patients with a high tumour burden. As described in
the Lyon-Sud cohort, patients with LP presented an interme-
diate or high FLIPI score with a high tumour burden in
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Fig 2. PRIMA study: Progression-free survival
(PFS) from registration according to leukaemic
phase At time of registration, 92 patients pre-
sented with follicular lymphoma with a detect-
able leukaemic phase (FL-LP) and 921 without.
Patients with LP had a shorter PFS than the
others. PRIMA: Primary RItuximab and
Maintenance. ClinicalTrials.gov number
NCT00140582 LC: presence/absence of
circulating lymphoma cells.
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most cases. They also frequently had elevated b2-microglobu-
lin level. Multivarite analysis identified the presence of
>4 9 109/l CLC as the most significant predictor indepen-
dently associated with an inferior TTP in this population of
patients with FL-LP.
Although retrospective, our series suggests that FL-LP is
associated with a poor outcome. This observation was
then confirmed in the PRIMA cohort. Interestingly, in this
population with FL-LP, TTP after first relapse was longer
than the first relapse-free interval (not shown), which might
be explained by the frequent use of ASCT as salvage therapy.
However, this population of FL-LP was not homogenous,
and our data suggest that only patients presenting with
>4 9 109/l CLC may have a significantly worst outcome. In
our series, the prognostic value of a CLC threshold of
4 9 109/l on TTP and OS was stronger than the impact of
established risk factors, such as the FLIPI score or b2-micro-
globulin level, as shown by the Cox regression model per-
formed in the matched population. To date in the literature,
the largest study focusing on patients with FL-LP included
10 retrospective cases (Al-nawakil et al, 2011). Only six of
these patients had concomitant LN involvement with a high
tumour burden and four had pure FL-LP with a diagnosis
relying on cytological examination and, for three of them,
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Fig 3. Time to progression (A) and overall
survival (B) in the matched population of 148
follicular lymphoma (FL) patients according to
circulating lymphoma cell (CLC) count (A)
The 15 patients with>4 9 109/l of CLC at
diagnosis have a worse median time to pro-
gression (15 and 89 respectively, P = 00001)
and overall survival (P = 0008) than the 133
patients with a CLC count ≤4 9 109/l. (B)
Those with no detectable CLC or with a CLC
count <4 9 109/l had a 5-year survival esti-
mate of 96% (standard error [SE] 17%) and a
10-years estimate of 88% (SE 48%) vs. 73%
(SE 13%) and 52% (SE 16%) for those with
≥4 9 109/l of CLC.
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cytogenetics or molecular biology. The authors suggested a
more indolent clinical evolution for these patients without
nodal involvement. The median follow up in the study
reported by Al-nawakil et al (2011) was 26 months, one of
the four patients was treated at diagnosis and one was lost to
follow-up. Another study reported the useful prognostic
value of high lymphocyte counts in FL but excluded patients
with FL-LP (Siddiqui et al, 2006). Recently, many advances
have been made in understanding the NHL microenviron-
ment (Drillenburg & Pals, 2000; Gribben, 2010; Guilloton
et al, 2012) and adhesion molecules have been shown to be
highly implicated in lymphoma tissue-specific homing, dis-
semination and aggressiveness of the disease. Recent reports
suggest that an increased serum level of cell adhesion mole-
cules in soluble form, such as CD44, intercellular adhesion
molecule 1 (ICAM1, CD54) or vascular cell adhesion mole-
cule 1 (VCAM1, CD106), is associated with a worse outcome
in aggressive lymphoma and in some indolent lymphomas
(Niitsu & Iijima, 2002; Shah et al, 2012). The elevated serum
level of CD54 is explained by proteolytic release of the mole-
cule from the malignant cells’ surface. Here the number of
FL cases that expressed CD54 was lower in the FL-LP group.
This suggests that, in FL-LP, cell surface CD54 could be
cleaved and released as its soluble form, which would be
consistent with the poorer prognosis of these patients.
Recently, an enhanced proliferation rate and clonogenic
capacity was found in cell lines with ectopic CD44 expression
(Higashi et al, 2009; Hu et al, 2010). In our study, CD44
was also found to be more frequently expressed in patients
with FL-LP.
Based on this data, patients with FL-LP at diagnosis
should be considered as having a more aggressive disease
course, relative to other indolent NHL. The same finding was
also reported in DLBCL, where the prognostic value of LP
has been recently associated with a worse outcome (Berger
et al, 2000; Nodit et al, 2003; Rubio-Moscardo et al, 2005;
Ondrejka et al, 2011; Muringampurath-John et al, 2012;
Nygren et al, 2012). Although approximately one-third of
the patients included in this series experienced long term
TTP, all patients should be monitored carefully during
and after first-line treatment to consider more intensive
treatment, such as ASCT, when feasible as a therapeutic
option to achieve a sustained response, especially if a
complete response is not achieved or if their disease
progresses shortly after their initial therapy.
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